Summary by Moomoo AI
NeuroSense Therapeutics Ltd., a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) for January 2024. The report includes an updated presentation of the company's business, which has been made publicly available as Exhibit 99.1. Notably, the presentation contains newly updated information on slides 4 and 29. NeuroSense emphasizes that the new data in the presentation does not constitute an admission of materiality. The company advises that the presentation's summary information should be viewed in conjunction with its SEC filings and other public disclosures, which may include press releases. The updated presentation is dated January 2024, and the Form 6-K was signed on behalf of NeuroSense Therapeutics Ltd. by Alon Ben-Noon on January 9, 2024.